GlaxoSmithKline Presents Innovative Neuroscienc...( PHILADELPHIA and LONDON Dec. 13 /...),Health

PHILADELPHIA and LONDON, Dec. 13 /PRNewswire-FirstCall/ -- GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience portfolio and the company's disease area strategy to investors and analysts at a meeting in New York.

Highlights

-- Innovative neuroscience pipeline spans 13 different disease areas

including Alzheimer's disease, depression, schizophrenia, and multiple

sclerosis (MS):

- More than 25 innovative compounds currently in development with 15

new mechanisms of action

-- New "proof of concept" data presented on promising phase II compounds

773812 for schizophrenia and 742457 for Alzheimer's disease:

- Both assets to progress to large-scale phase IIb trials assessing

efficacy and safety compared to leading marketed therapies

-- Phase II program for use of ofatumumab in multiple sclerosis

announced, with trials involving approximately 300 patients starting in

2008:

-- Phase III treatment, 1838262, profiled:

- Filing for restless legs syndrome (RLS) expected in third quarter of

2008

- New phase III program for migraine prophylaxis planned

- New phase II studies in neuropathic pain announced

-- Four CNS products with potential to be launched or approved in 2008:

- Trexima potential "new gold standard" for migraine;

- Lamictal XR new once daily treatment for epilepsy;

- Lunivia, a successful treatment for insomnia in the US, expected to

be launched in Europe;

- Requip XL the first non-ergot once daily dopamine agonist for the

treatment of Parkinson's disease

-- Overall pipeline progress continues:

- 8 approvals, 8 filings and 9 key assets starting phase III trials so

far in 2007

- GSK confirms FDA filing of Promacta, a new oral treatment for short-'/>"/>